Erasca shares closed at $21.49 on April 24, 2026. Four days later they closed at $9.90. In between, the company disclosed a patent dispute and a patient death in the same drug trial, both on April 27.
Investors who bought Erasca securities between January 14, 2025, and April 26, 2026, have until August 10, 2026, to ask the court to make them lead plaintiff in the resulting securities class action. The case, Cheng v. Erasca, Inc. (No. 26-cv-03481), is pending in the Southern District of California.
Two disclosures, one day
The first came before the market opened on April 27. In a Form 8-K, Erasca said it had received a letter from lawyers for Revolution Medicines, or RevMed. The letter alleged that Erasca’s ERAS-0015 infringes a RevMed patent, U.S. Patent No. 12,409,225, and ties into alleged trade secret misappropriation. It also said Erasca had “improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures.” The stock fell $2.34, about 10.9 percent, to $19.15.
At about 4:17 p.m. EDT that day, Erasca filed a second 8-K with preliminary Phase 1 data for ERAS-0015. One patient given 24 mg had died roughly a month after starting treatment. The company classified it as a “Grade 3 TRAE of pneumonitis” that “progressed to Grade 5 after withdrawal of supportive care per patient decision.” The filing also said comparisons between ERAS-0015 and other candidates, RMC-6236 among them, were “not based on any head-to-head clinical trials.”
The next day the stock lost $9.25, more than 45 percent.
What the suit says
The complaint accuses Erasca and certain executives of making false or misleading statements, or leaving out facts. It says ERAS-0015’s preclinical data rested on improper comparisons to RevMed’s compound, exposing Erasca to patent and trade secret risk, and that the company therefore had no reasonable basis for its positive statements about the drug. One account of the complaint says Erasca marketed the therapy as “best-in-class,” citing results that supposedly beat RevMed’s RMC-6236, and that the drug targets RAS-mutated solid tumors.
Several firms have put out notices. Faruqi & Faruqi, which issued its reminder on August 9, directs investors to partner Josh Wilson at 877-247-4292 or 212-983-9330, extension 1310. Kahn Swick & Foti, led by former Louisiana Attorney General Charles C. Foti, Jr., names managing partner Lewis Kahn at 1-877-515-1850. Rosen Law Firm is also representing investors.
The lead plaintiff is usually the investor with the largest financial interest, and that person directs the case for the class. Nobody has to take that role to be paid. Class members can do nothing and still share in any recovery, and the firms say the case runs on contingency, with no out-of-pocket cost to investors. The court has not yet certified a class.
Sources
- ERAS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
- Investors Face August Deadline in Erasca Securities Fraud Lawsuit
- Erasca Investors Face August Deadline in Securities Class Action





